Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Search
Search results
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Ben Ramus: Our epic challenge for Retina UK
This July, Ben Ramus will lead a group of twelve adventurers as they take on the renowned National Three Peaks Challenge, in aid of national sight loss charity, Retina UK. Ben has decided to take on the epic challenge in recognition of two of his uncles’ sight loss journey, as they live with the rare inherited sight loss condition, retinitis pigmentosa.
Flipping the switch on RP: SparingVision doses patients in their first in-human clinical trial for SPVN20
The latest research news from Retina UK.
PDE6A gene therapy trial report: the importance of scientific learnings in an unsuccessful trial
Researchers from the University Hospital Tübingen in Germany recently announced that there were no signs of visual gains in an early-phase clinical trial of a PDE6A gene therapy for Retinitis Pigmentosa (RP).
Download our Knowledge-base material
Download copies of our Knowledge-base material
Meet our Trustee: Rob Halliwell
Rob is a Chief Technology Officer based in Manchester, with over 20 years’ experience leading technology, software development and digital transformation.
Completed Research Project Outcomes
The following projects were being funded by Retina UK and have recently come to an end.
Meet our community: The Kearney family
Emily Kearney is mum to four boys, aged four to 13, two of whom are living with an inherited sight loss condition.
Look Forward – Summer 2022 – Issue 177
We’re all still buzzing from our recent conferences. We do hope you enjoyed them as much as we did. If you weren’t able to join us, then you can watch or listen to the recordings on our website.